Wearable injectors market forecast to reach $19.77 billion by 2030

The Business Research Company says the wearable injectors market is growing fast as chronic disease rates rise and home-based drug delivery becomes more common. The market is projected to expand from $9.84 billion in 2025 to $19.77 billion by 2030, with North America holding the largest share in 2025.

Why it matters: - Wearable injectors are gaining traction as patients and providers look for easier ways to deliver drugs outside clinical settings. - The market’s projected growth points to stronger demand for self-administration, home healthcare, and connected drug delivery systems. - Rising chronic disease burdens are expanding the addressable patient pool for long-duration injectable therapies.

What happened: - The Business Research Company released a wearable injectors market report on Sept. 3, 2026. - The report says the market will grow from $9.84 billion in 2025 to $11.32 billion in 2026. - The report projects the market will reach $19.77 billion by 2030. - The forecast implies a 15.0% compound annual growth rate from 2025 through 2030. - North America held the largest share of the wearable injectors market in 2025. - Western Europe ranked as the second-largest regional market in 2025.

The details: - Wearable injectors attach to the body and deliver medication subcutaneously over a set period. - The devices support controlled and continuous dosing. - The report links near-term growth to chronic disease prevalence, greater use of biologics and large-molecule drugs, wider self-administration therapies, drug formulation advances, and broader acceptance of wearable delivery systems. - Longer-term growth is tied to personalized medicine, home-based healthcare, connected drug delivery systems, longer-duration injectors, and tighter integration with digital health platforms. - The report highlights higher uptake of on-body drug delivery devices and more demand for continuous medication administration. - The report also points to smart connectivity features, growth in home injectable therapies, and efforts to improve patient adherence. - The market report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The 2026 report format includes market attractiveness scoring, total addressable market analysis, a company scoring matrix, Excel-based dashboards, market hotspots infographics, and technology and future-trend analysis. - The report offers a free sample at the sample page. - The full report is available here.

Between the lines: - The growth story is less about a single device category and more about a broader shift toward care at home and longer, steadier treatment delivery. - Chronic diseases such as diabetes, cardiovascular disease, and cancer create recurring demand for devices that reduce clinic visits and support adherence. - The inclusion of connected and digital-health features suggests wearable injectors are moving closer to the larger remote-care ecosystem. - In April 2023, the British Diabetic Association reported about 4.3 million people in the UK had diabetes, with nearly 90% diagnosed with type 2 diabetes, 8% with type 1, and 2% with other types.

What's next: - The market is expected to keep expanding through 2030 as personalized medicine and home injection therapies advance. - Demand for longer-duration, connected wearable injectors will likely increase as healthcare systems push more treatment into the home. - The report points to continued work on patient adherence and continuous dosing as key product priorities.

The bottom line: - Wearable injectors are moving from a niche drug-delivery option to a core part of the home-care and biologics delivery landscape.